Intellia Therapeutics Inc.

Company Overview

Intellia Therapeutics Inc. develops curative genome-editing treatments using CRISPR-Cas9 to help people with severe and life-threatening diseases. The company focuses on creating therapies for genetic disorders and engineered cell therapies for immuno-oncology and autoimmune diseases. Their modular platform supports in vivo and ex vivo approaches for various therapeutic targets. Intellia has generated preclinical data indicating the potential for single-administration cures for genetic diseases.

The company has in vivo candidates, NTLA-2001 for ATTR amyloidosis and NTLA-2002 for hereditary angioedema, as the first CRISPR/Cas9 IV-administered therapies for precision gene editing in humans. The company is expanding ex vivo programs for treating immuno-oncology and autoimmune diseases independently and through partnerships to develop treatments that modify patient cells outside the body before reinfusion.

Financial Highlights (FY 2024)

Company's Business Segments

• Genome Editing-based Therapies : This segment provides therapeutics using CRISPR/Cas9-based technologies by leveraging the company's modular platform to advance in-vivo and ex-vivo therapies for diseases with high unmeeted needs.